Read news on Pan-TEAD inhibitor with our app.
Read more in the app
Insilico Medicine reports 40% ORR at 130 mg for Pan-TEAD inhibitor ISM6331 designed using generative AI in heavily pretreated mesothelioma at ESMO 2026
